Phase 1 results show that SUL-238 is safe, well-tolerated, and demonstrates favorable pharmacokinetics with high CSF penetration in healthy elderly volunteers, supporting its advancement into further ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results